Publications

最近7年代表性期刊論文

  1. Li, C.Y., Chou, T.F., Lo, Y.L.* An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: in vitro investigations. International Journal of Biological Macromolecules 2024; 254: 127905 (SCI; IF=8.2; Rank = 5.38% by IF in Polymer Science; USA patent and Taiwan patent application: under review).
  2. Lin, S.Y., Wang, Y.Y., ……., Lo, Y.L., Chang, Y.H., Chen, C.J.* DHA alleviated hepatic and adipose inflammation with increased adipocyte browning in high-fat diet-induced obese mice. The Journal of Nutritional Biochemistry 2023; 122: 109457.
  3. Lo, Y.L.*, Lin, H.C., Tseng, W.H. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer. Acta Biomaterialia 2022; 153: 465 (SCI; IF=70; Rank = 9.38% by IF in Engineering, Biomedical; US patent and Taiwan patent).
  4. Lo, Y.L.*, Wang, T.Y., Chen, C.J., Chang, Y.H., Lin, A.M.Y.* Two-in-one nanoparticle formulation to deliver a tyrosine kinase inhibitor and microRNA for targeting metabolic reprogramming and mitochondrial dysfunction in gastric cancer. Pharmaceutics 2022; 14(9): 1759 (SCI; IF = 5.4; Rank = 10.22% by JCI in Pharmacology & Pharmacy; 榮獲2022年榮總台灣聯合大學系統第18期合作研究成果發表會壁報論文獎第二名; 2023年第19屆榮台聯大優良論文獎第三名).
  5. Chang, Y.H., …Lo, Y.L., Chen, C.J., Tsai, H.F., Shiau, M.Y. Implication of adipogenesis-coupled CRMP2 functional profile in metabolic homeostasis and imbalance. Biomedicines2022;10(10):2603 (SCI; IF = 4.76; Rank = 30.82% by IF in Pharmacology & Pharmacy).
  6. Chang, Y.H., …Lo, Y.L., Chen, C.J., Tsai, H.F., Shiau, M.Y. Characterization of collapsin response mediator protein 2 in colorectal cancer progression in subjects with diabetic comorbidity. Cells2022;11(4):727 (SCI; IF = 7.67; Rank = 26.29% by IF in Cell Biology).
  7. Wang, C.S., Chang, C.H., Tzeng, T.Y., Lin, A.M.Y., Lo, Y.L.* Gene-editing by CRISPR-Cas9 in combination with anthracycline therapy via tumor microenvironment-switchable, EGFR-targeted, and the nucleus-directed nanoparticles for head and neck cancer suppression. Nanoscale Horizons 2021; 6(9): 729 (SCI; IF = 9.7; Rank = 14.33% by IF in Materials Science, Multidisciplinary). 被選為2021第6卷第9期封底 (outside back cover).
  8. Lo, Y.L.*, Lin, H.C., Hong, S.T., Chang, C.H., Wang, C.S., Lin, A.M.Y.* Lipid polymeric nanoparticles modified with tight junction-modulating peptides promote afatinib delivery across a blood–brain barrier model. Cancer Nanotechnology 2021; 12: 13 (SCI; IF=5.7; Rank = 25.73% by IF in Oncology).
  9. Huang, H.J., Wang, H.T., Yeh, T.Y., Lin, B.W., Shiao, Y.J., Lo, Y.*, Lin, A.M.Y.* Neuroprotective effect of selumetinib on acrolein-induced neurotoxicity. Scientific Reports 2021; 11: 12497 (SCI; IF = 4.6; Rank 15.79% by JCI in Multidisciplinary Sciences).
  10. Lo, Y.L.*, Wang, C.S., Chen, Y. C., Wang, T.Y., Chang, Y.H., Chen, C.J., Yang, C.P. Mitochondrion-directed nanoparticles loaded with a natural compound and a microRNA for promoting cancer cell death via the modulation of tumor metabolism and mitochondrial dynamics. Pharmaceutics 2020; 12(8): 756 (SCI; IF = 5.4; Rank = 10.22% by JCI in Pharmacology & Pharmacy; 榮獲2021年第17屆榮台聯大優良論文獎第三名與第18期合作研究成果發表會壁報論文獎第二名).
  11. Lin, Y.Y., Yang, Y.Y., Wei-Yi Lai, Chian-Shiu Chien, Shih-Jen Chen, De-Kuang Hwang, Ying-Hsiu Lai, Tai-Chi Lin, Shih-Hwa Chiou, Lo, Y.L., Teh-Ia Huo, Yueh Chien*. Development of polydimethylsiloxane-based biomimetic scaffolds with cylinder micropillars for retinal pigment epithelial cell cultivation. J Chin Med Assoc.2020; 83(11):1029. (SCI; IF = 3.4; Rank = 71% by JCI in Medicine, General & Internal)
  12. Lo, Y.L.*, Chang, C.H., Wang, C.S., Yang, M.H., Lin, A.M.Y., Hong, C.J., Tseng, W.H. PEG-coated nanoparticles detachable in acidic microenvironments for the tumor-directed delivery of chemo- and gene therapies for head and neck cancer. Theranostics 2020; 10(15): 6695 (SCI; IF= 12.4; Rank = 5.88% by IF in Medicine, Research & Experiment; US patent and Taiwan patent).
  13. Lin, S.Y., Yang, C.P., Wang, Y.Y., Hsiao, C.W., Chen, W.Y., Lai, S.L., Lo, Y.L., Chang, Y.H., Hong, C.J., Chen, C.J.* Interleukin-4 improves metabolic abnormalities in leptin deficient and high-fat diet mice. J. Mol. Sci. 2020; 21(12): 4451 (SCI; IF = 5.6; Rank = 23.16% by IF in Biochemistry & Molecular Biology).
  14. Juang, V., Chang, C.H., Wang, C.S., Chen, Y.C., Wang, H.E., Lo, Y.L.* pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small 2019; 15(49):e1903296 (SCI; IF = 3; Rank = 8.48% by IF in Materials Science, Multidisciplinary; US patent and Taiwan patent).
  15. Hong, S.T., Lin, H.C., Wang, C.S., Chang, C.H., Lin, A.M.Y., Yang, C.H.J., Lo, Y.L.* Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. J Nanobiotechnology 2019;17(1):89 (SCI; IF = 10.2; Rank = 7.69% by IF in Biotechnology & Applied Microbiology).
  16. Lo, Y.L.*, Y.C. Chen, C.H. Chang, W.H. Tseng, C.S. Wang. Tumor-targeted and pH-shiftable nanoparticles to encapsulate oxaliplatin and microRNA for colorectal cancer therapy. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Sup l): Abstract A100.
  17. Chen, J., Hsu, C.C., Shiao, Y.J., Wang, H.T., Lo, Y.L.*, Lin, A.M.Y.* Anti-inflammatory effect of afatinib (an EGFR-TKI) on OGD-induced neuroinflammation. Scientific Reports 2019; 9(1): 2516 (SCI; IF = 4.6; Rank 15.79% by JCI in Multidisciplinary Sciences).
  18. Yang, C.P., Shiau, Y., Lai, Y.R., Ho, K.T., Hsiao, C.W., Chen, C.J., Lo, Y.L., Chang, Y.H.* Interleukin-4 boosts insulin-induced energy deposits by enhancing glucose uptake and lipogenesis in hepatocytes. Oxid Med Cell Longev. 2018; 6923187 (SCI; IF = 7.31; Rank = 28.35% by IF in Cell Biology).
  19. Zhao, W.Z., Wang, H.T., Huang, H.J., Lo, Y.*, Lin, A.M.Y.* Neuroprotective effects of baicalein on acrolein-induced neurotoxicity in the nigrostriatal dopaminergic system of rat brain. Molecular Neurobiology 2018; 55(1): 130 (SCI; IF=5.1; Rank = 20.92% by JCI in Neurosciences).
  20. Lin, G.L., Ting, H.J., Tseng, T.C., Juang, V., Lo, Y.L.* Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells. PLoS One 2017; 12(10): e0185625 (SCI; IF = 3.7; Rank = 21.05% by JCI in Multidisciplinary Sciences).
  21. Wang, H.T.*, Lin, J.H., Yang, C.H, Huang, C.H., Weng, C.W., Lin, A.M.Y., Lo, Y.L., Chen, W.S., Tang, M.S. Acrolein induces mtDNA damages, mitochondrial fission and mitophagy in human lung cells. Oncotarget 2017; 8: 70406 (SCI; IF = 5.168; Rank = 20.28% by IF in Oncology).
  22. Wang, Y.T., Lin, H.C., Zhao, W.Z., Huang, H.J., Lo, Y.L., Wang, H.T.*, Lin, A.M.Y.* Acrolein acts as a neurotoxin in the nigrostriatal dopaminergic system of rat: involvement of α-synuclein aggregation and programmed cell death. Scientific Reports 2017; 7: 45741-45749 (SCI; IF = 0; Rank 14.18% by JCI in Multidisciplinary Sciences).
  23. Lin, K.H., Hong, S.T., Wang, H.T., Lo, Y.L.*, Lin, A.M.Y.*, Yang, C.H.J. (2016) Enhancing anticancer effect of gefitinib across the blood-brain barrier model using liposomes modified with one alpha-helical cell-penetrating peptide or glutathione and Tween 80. J. Mol. Sci. 2016; 17 (12): 1998-2014 (SCI; IF = 5.6; Rank = 23.16% by IF in Biochemistry & Molecular Biology).
  24. Juang, V., Lee, H.P., Lin, A.M.Y., Lo, Y.L.* Cationic PEGylated liposomes incorporating an antimicrobial peptide hepcidin 2-3: an adjuvant of epirubicin to overcome multidrug resistance in cervical cancer cells. J. Nanomedicine 2016; 11: 6047–6064 (SCI; IF = 8.0; Rank = 6.50% by IF in Pharmacology & Pharmacy).

近期文章

近期留言

尚無留言可供顯示。

彙整

分類